Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma

R. Rosso, T. Mazzei, A. Sobrero, E. Mini, G. Cartei, P. Conte, R. Labianca, F. Cartei, A. Falcone, G. Pancera, G. Barsanti, F. Di Costanzo, A. Guglielmi, E. Bolli, L. Tixi, C. Aschele, A. Ribecco, P. Periti

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Between February 1991 and July 1992, 79 previously untreated patients with metastatic colorectal carcinoma were enrolled in a phase II study of combined 5-fluorouracil (5-FU) and l-folinic acid (FA). 5-FU 370 mg/m2/day was administered for 5 consecutive days as an intravenous (i.v.) bolus injection preceded by l-FA 100 mg/m2/day with the same administration modality. Treatment was given every 4 weeks until progression. 79 patients were evaluable for toxicity and 64 for response. 2 patients (3%) achieved a complete remission and 8 (12.5%) a partial remission, 33 (52%) had stable disease and 21 patients (33%) had progressive disease. Median duration of remission was 32.5 weeks and median survival for all evaluable patients was 64.5 weeks. Substantial to severe side-effects occurred in 39% of patients. Dose-limiting toxicity (grade 3-4) was mainly diarrhoea (18%) and mucositis (15%). Nausea/vomiting, cutaneous toxicity, leucopenia, alopecia and conjunctivitis of grade 3-4 occurred respectively in 6, 4, 2.5, 1 and 1% of cases. Toxicity appeared to be substantially similar to that characteristic of combined 5-FU and the chiral mixture of d,l-FA. Efficacy was within the range of that observed with the 5-FU d,l-FA combination, although at the lower level.

Original languageEnglish
Pages (from-to)338-343
Number of pages6
JournalEuropean Journal of Cancer
Volume30
Issue number3
DOIs
Publication statusPublished - 1994

Fingerprint

Leucovorin
Fluorouracil
Colorectal Neoplasms
Therapeutics
Mucositis
Conjunctivitis
Alopecia
Leukopenia
Intravenous Injections
Nausea
Vomiting
Diarrhea
Skin
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma. / Rosso, R.; Mazzei, T.; Sobrero, A.; Mini, E.; Cartei, G.; Conte, P.; Labianca, R.; Cartei, F.; Falcone, A.; Pancera, G.; Barsanti, G.; Di Costanzo, F.; Guglielmi, A.; Bolli, E.; Tixi, L.; Aschele, C.; Ribecco, A.; Periti, P.

In: European Journal of Cancer, Vol. 30, No. 3, 1994, p. 338-343.

Research output: Contribution to journalArticle

Rosso, R, Mazzei, T, Sobrero, A, Mini, E, Cartei, G, Conte, P, Labianca, R, Cartei, F, Falcone, A, Pancera, G, Barsanti, G, Di Costanzo, F, Guglielmi, A, Bolli, E, Tixi, L, Aschele, C, Ribecco, A & Periti, P 1994, 'Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma', European Journal of Cancer, vol. 30, no. 3, pp. 338-343. https://doi.org/10.1016/0959-8049(94)90253-4
Rosso, R. ; Mazzei, T. ; Sobrero, A. ; Mini, E. ; Cartei, G. ; Conte, P. ; Labianca, R. ; Cartei, F. ; Falcone, A. ; Pancera, G. ; Barsanti, G. ; Di Costanzo, F. ; Guglielmi, A. ; Bolli, E. ; Tixi, L. ; Aschele, C. ; Ribecco, A. ; Periti, P. / Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma. In: European Journal of Cancer. 1994 ; Vol. 30, No. 3. pp. 338-343.
@article{edc256b24639471cbe8ae0a0e186edfa,
title = "Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma",
abstract = "Between February 1991 and July 1992, 79 previously untreated patients with metastatic colorectal carcinoma were enrolled in a phase II study of combined 5-fluorouracil (5-FU) and l-folinic acid (FA). 5-FU 370 mg/m2/day was administered for 5 consecutive days as an intravenous (i.v.) bolus injection preceded by l-FA 100 mg/m2/day with the same administration modality. Treatment was given every 4 weeks until progression. 79 patients were evaluable for toxicity and 64 for response. 2 patients (3{\%}) achieved a complete remission and 8 (12.5{\%}) a partial remission, 33 (52{\%}) had stable disease and 21 patients (33{\%}) had progressive disease. Median duration of remission was 32.5 weeks and median survival for all evaluable patients was 64.5 weeks. Substantial to severe side-effects occurred in 39{\%} of patients. Dose-limiting toxicity (grade 3-4) was mainly diarrhoea (18{\%}) and mucositis (15{\%}). Nausea/vomiting, cutaneous toxicity, leucopenia, alopecia and conjunctivitis of grade 3-4 occurred respectively in 6, 4, 2.5, 1 and 1{\%} of cases. Toxicity appeared to be substantially similar to that characteristic of combined 5-FU and the chiral mixture of d,l-FA. Efficacy was within the range of that observed with the 5-FU d,l-FA combination, although at the lower level.",
author = "R. Rosso and T. Mazzei and A. Sobrero and E. Mini and G. Cartei and P. Conte and R. Labianca and F. Cartei and A. Falcone and G. Pancera and G. Barsanti and {Di Costanzo}, F. and A. Guglielmi and E. Bolli and L. Tixi and C. Aschele and A. Ribecco and P. Periti",
year = "1994",
doi = "10.1016/0959-8049(94)90253-4",
language = "English",
volume = "30",
pages = "338--343",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "3",

}

TY - JOUR

T1 - Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma

AU - Rosso, R.

AU - Mazzei, T.

AU - Sobrero, A.

AU - Mini, E.

AU - Cartei, G.

AU - Conte, P.

AU - Labianca, R.

AU - Cartei, F.

AU - Falcone, A.

AU - Pancera, G.

AU - Barsanti, G.

AU - Di Costanzo, F.

AU - Guglielmi, A.

AU - Bolli, E.

AU - Tixi, L.

AU - Aschele, C.

AU - Ribecco, A.

AU - Periti, P.

PY - 1994

Y1 - 1994

N2 - Between February 1991 and July 1992, 79 previously untreated patients with metastatic colorectal carcinoma were enrolled in a phase II study of combined 5-fluorouracil (5-FU) and l-folinic acid (FA). 5-FU 370 mg/m2/day was administered for 5 consecutive days as an intravenous (i.v.) bolus injection preceded by l-FA 100 mg/m2/day with the same administration modality. Treatment was given every 4 weeks until progression. 79 patients were evaluable for toxicity and 64 for response. 2 patients (3%) achieved a complete remission and 8 (12.5%) a partial remission, 33 (52%) had stable disease and 21 patients (33%) had progressive disease. Median duration of remission was 32.5 weeks and median survival for all evaluable patients was 64.5 weeks. Substantial to severe side-effects occurred in 39% of patients. Dose-limiting toxicity (grade 3-4) was mainly diarrhoea (18%) and mucositis (15%). Nausea/vomiting, cutaneous toxicity, leucopenia, alopecia and conjunctivitis of grade 3-4 occurred respectively in 6, 4, 2.5, 1 and 1% of cases. Toxicity appeared to be substantially similar to that characteristic of combined 5-FU and the chiral mixture of d,l-FA. Efficacy was within the range of that observed with the 5-FU d,l-FA combination, although at the lower level.

AB - Between February 1991 and July 1992, 79 previously untreated patients with metastatic colorectal carcinoma were enrolled in a phase II study of combined 5-fluorouracil (5-FU) and l-folinic acid (FA). 5-FU 370 mg/m2/day was administered for 5 consecutive days as an intravenous (i.v.) bolus injection preceded by l-FA 100 mg/m2/day with the same administration modality. Treatment was given every 4 weeks until progression. 79 patients were evaluable for toxicity and 64 for response. 2 patients (3%) achieved a complete remission and 8 (12.5%) a partial remission, 33 (52%) had stable disease and 21 patients (33%) had progressive disease. Median duration of remission was 32.5 weeks and median survival for all evaluable patients was 64.5 weeks. Substantial to severe side-effects occurred in 39% of patients. Dose-limiting toxicity (grade 3-4) was mainly diarrhoea (18%) and mucositis (15%). Nausea/vomiting, cutaneous toxicity, leucopenia, alopecia and conjunctivitis of grade 3-4 occurred respectively in 6, 4, 2.5, 1 and 1% of cases. Toxicity appeared to be substantially similar to that characteristic of combined 5-FU and the chiral mixture of d,l-FA. Efficacy was within the range of that observed with the 5-FU d,l-FA combination, although at the lower level.

UR - http://www.scopus.com/inward/record.url?scp=0028241595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028241595&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(94)90253-4

DO - 10.1016/0959-8049(94)90253-4

M3 - Article

VL - 30

SP - 338

EP - 343

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 3

ER -